SCHEMBL4705282

SCHEMBL4705282

CC(C)(C)OC(=O)N1CCCC(C(=O)N2CCC(c3cccnc3)C2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.52
HPGD P15428 1/20 0.48
HSD11B1 P28845 2/20 0.47
SPR P35270 1/20 0.46
PDE4B Q07343 1/20 0.46
ALDH1A1 P00352 4/20 0.45
MAPT P10636 3/20 0.45
HTT P42858 1/20 0.45
TP53 P04637 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CCNK O75909 1/20 0.45
CDK12 Q9NYV4 1/20 0.45
LMNA P02545 2/20 0.45
HPGDS O60760 2/20 0.44
CHRNA7 P36544 2/20 0.44
CHRNB2 P17787 2/20 0.44
CHRNB4 P30926 2/20 0.44
CHRNA3 P32297 2/20 0.44
CHRNA4 P43681 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14497248 0.92 GPR119 (0.60) GPR119HSD11B1SPRPDE4BMAPT
SCHEMBL30417389 0.92 GPR119 (0.60) GPR119HSD11B1SPRPDE4BMAPT
SCHEMBL25274630 0.90 GPR119 (0.56) GPR119HSD11B1SPRPDE4BALDH1A1
SCHEMBL31339129 0.90 GPR119 (0.56) GPR119HSD11B1SPRPDE4BALDH1A1
SCHEMBL3154994 0.85 GPR119 (0.65) GPR119HSD11B1MAPT
SCHEMBL20757936 0.82 GPR119 (0.55) GPR119HSD11B1ALDH1A1MAPTMEN1
SCHEMBL30098458 0.82 GPR119 (0.55) GPR119HSD11B1ALDH1A1MAPTMEN1
SCHEMBL16460192 0.81 KLK7 (0.56) GPR119HPGDHSD11B1ALDH1A1MAPT
SCHEMBL15530741 0.81 NAMPT (0.61) GPR119HPGDALDH1A1MAPTHTT
SCHEMBL21845587 0.79 PDE4B (0.54) GPR119HPGDPDE4BMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758882-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-23 EP disclosed
EP-1758882-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-03-07 EP disclosed
WO-2006012173-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20050288317-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288317-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 GPR119 290/4885HPGD 51/4885HSD11B1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.